PreciDIAB is unique in its kind in France
PreciDIAB is the first in class collaborative venture between Lille world-class scientists, multidisciplinary clinicians, health industry and innovative start-ups, patients and professional diabetes associations, strongly supported by national and local authorities which are all committed to achieving a simple but highly ambitious objective: to develop new solutions to control diabetes and comorbidities and to offer diabetic patients diabetes the same quality of life and longevity as non-diabetics, at reasonable costs.
Diabetes is a paradigm of modern life related affliction burdens. Diabetes affects 420M patients worldwide (4M in France), increasing to 700M by 2030. Diabetes is the 6th cause of mortality and a leading cause of disability. Hence, diabetes costs are enormous and uncontrolled, and harm health systems worldwide. Only a dramatic reduction of diabetes degenerative complications will reverse this disastrous trend. It is possible! The Danish Steno-2 randomized trial has recently demonstrated over 21-year follow-up that transient intensified treatment of type 2 diabetes is associated with a lifespan increase of 8 years. Now, to move from a pioneer study to the real world, we need to improve the standard of care in clinical practice: this is PreciDIAB’s mission. To change the diabetes healthpath, PreciDIAB will develop a groundbreaking holistic approach of personalized prevention and care, thanks to a multidisciplinary team using multi-omics approaches, involving and training the best academic talents, main industry stakeholders, and working to a comprehensive and professionally managed work program.
PreciDIAB is built on strongest bases in Lille University Hospital and beyond.
PreciDIAB original pillars are:
PreciDIAB holistic approach for a personal diabetes care can make
a significant difference in diabetic patients’ life in France and elsewhere !